Loading clinical trials...
Loading clinical trials...
Open Label Phase I Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia (With Pilot Feasibility Study in Combination With Pegylated Interferon Alfa 2a for Patients Who do Not Respond to the Single Agent at Each Dose Level)
Conditions
Interventions
RG7388
Pegasys
Locations
3
United States
Georgetown University Medical Center
Washington D.C., District of Columbia, United States
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Wake Forest University Baptist Medical Center
Winston-Salem, North Carolina, United States
Start Date
April 1, 2015
Primary Completion Date
December 19, 2018
Completion Date
December 19, 2018
Last Updated
September 12, 2019
NCT06456346
NCT06343805
NCT05123365
NCT04645199
NCT06063486
NCT06541249
Lead Sponsor
John Mascarenhas
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions